<DOC>
	<DOCNO>NCT00696072</DOCNO>
	<brief_summary>The purpose study find effect combination letrozole ( brand name : Femara ) dasatinib ( brand name : Sprycel ) metastatic breast cancer compare letrozole alone</brief_summary>
	<brief_title>Randomized Phase II Trial Letrozole With Without Dasatinib First Second-line Treatment Hormone Receptor-positive , HER2-negative Post-menopausal Breast Cancer That Unresectable , Locally Recurrent Metastatic</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Has histologic cytologic diagnosis breast cancer ; evidence unresectable locally recurrent metastatic disease Has measurable evaluableonly disease Is female , â‰¥18 yr age , post menopausal surgically sterile HER2 negative , HR+ , ER+ and/or PgR+ breast cancer 01 prior chemotherapy regimen metastatic disease . Prior adjuvant neoadjuvant chemotherapy complete least 1 month prior Prior tamoxifen therapy allow No AI therapy &gt; 1 year without recurrence Pregnant breast feed Prior hormonal therapy metastatic locally recurrent disease &gt; 1 chemotherapy regimen metastatic disease Pleural pericardial effusion Serious cardiac condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>